ebook: How to start your own lab
Learn practical tips from eight Principal Investigators about how to start your own lab.
List view / Grid view
Medical screening is a strategy used to identify the possible presence of an as-yet-undiagnosed disease in individuals without signs or symptoms.
Learn practical tips from eight Principal Investigators about how to start your own lab.
Collaborative research has revealed two hallmarks of COVID-19 infection associated with more severe symptoms that can be identified by a blood test.
Researchers are utilising computers to aid in their investigations into a COVID-19 treatment. Here, we highlight three studies using simulations, calculations and AI to identify a drug to combat the coronavirus.
Learn how you could use high-content analysis for functional & phenotypic assays in your infectious disease research or drug discovery.
Bioassays and thin-layer chromatography has been used by scientists to analyse molecules in plant extracts as a fast and cost-effective method for identifying new drug compounds.
7 May 2020 | By PerkinElmer
High-throughput screening (HTS) cascades have evolved to ensure that high quality hits can be identified from large screening collections.
David Johnson of GigaGen discusses how recombinant forms of intravenous immunoglobulins (IVIG) could overtake current IVIG therapies and be used in the treatment of COVID-19.
A series of three new assays to screen for drug compounds or proteins that combat the COVID-19 coronavirus has been developed.
Bringing together protein science, drug discovery experience and innovative technology, a new collaboration aims to identify novel drug targets for COVID-19.
A new study has revealed that less than 10 percent of respiratory and intestinal cells are susceptible to SARS-CoV-2 infection and expression of ACE2 receptors is driven by the body's immune response.
The developers of a novel method to create immunological assay probes for screening T cells has leveraged their new protocol against COVID-19.
High-throughput screening of thousands of compounds has revealed several candidates, including lead compound ebselen, with the potential for treating COVID-19.
A collaboration between academia and industry has produced an assay and new screening technique which utilises directed evolution for the discovery of antibody-based drugs.
There are heightened levels of abnormal stem cells in the lungs of COPD patients, presenting a drug target that researchers are screening compounds against.
After screening 300 antibodies, Celltrion has identified the 14 most powerful that could potentially combat the COVID-19 coronavirus.